Biosynex Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Larry Abensur

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	9.3yrs
Participación del CEO	6.2%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	9.3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Larry Abensur

9.3yrs

Permanencia

Mr. Larry Abensur has served as a Director at Biosynex S.A. since June 24, 2015 and serves as the Chief Executive Officer at Biosynex SA. He serves as the Chairman of Biosynex S.A. Mr. Abensur serves as th...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Larry Abensur	Chairman & CEO	9.3yrs	sin datos	6.2% € 2.8m
Thierry Paper	Deputy CEO & Director	9.3yrs	€96.00k	0.99% € 444.7k
Thomas Lamy	Deputy CEO & Director	9.3yrs	sin datos	1.56% € 698.8k
Felix Agbalika	Member of Scientific Advisory Board	no data	sin datos	sin datos
Emmanuel Drouet	Member of Scientific Advisory Board	no data	sin datos	sin datos
Denis Gallot	Member of Scientific Advisory Board	no data	sin datos	sin datos
Vincent Sapin	Member of Scientific Advisory Board	no data	sin datos	sin datos
Marc Noizet	Member of Scientific Advisory Board	no data	sin datos	sin datos
Elie Fraenckel	Director	no data	sin datos	sin datos

9.3yrs

Permanencia media

Junta con experiencia: La junta directiva de 0DL se considera experimentada (9 años de antigüedad promedio).

Biosynex Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Biosynex SA, Annual General Meeting, Jun 07, 2024

No independent directors

No independent directors

Recent updates

New major risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

New minor risk - Shareholder dilution

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 24%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Full year 2020 earnings released: EPS €3.43 (vs €0.12 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

CEO

Permanencia

Miembros de la Junta

Permanencia media